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Abstract
Background: Large tumor motion often leads to larger treatment volumes, especially the lung tumor located in lower
lobe and adhered to chest wall or diaphragm. The purpose of this work is to investigate the impacts of planning target
volume (PTV) margin on Stereotactic Body Radiotherapy (SBRT) in non-small cell lung cancer (NSCLC).
Methods: Subjects include 20 patients with the lung tumor located in lower lobe and adhered to chest wall or
diaphragm who underwent SBRT. Four-dimensional computed tomography (4DCT) were acquired at simulation to
evaluate the tumor intra-fractional centroid and boundary changes, and Cone-beam Computer Tomography (CBCT)
were acquired during each treatment to evaluate the tumor inter-fractional set-up displacement. The margin to
compensate for tumor variations uncertainties was calculated with various margin calculated recipes published in the
exiting literatures.
Results: The means (±standard deviation) of tumor centroid changes were 0.16 (±0.13) cm, 0.22 (±0.15) cm, and 1.37
(±0.81) cm in RL, AP, and SI directions, respectively. The means (±standard deviation) of tumor edge changes were 0.21
(±0.18) cm, 0.50 (±0.23) cm, and 0.19 (±0.44) cm in RL, AP, and SI directions, respectively. The means (±standard
deviation) of tumor set-up displacement were 0.03 (±0.24) cm, 0.02 (±0.26) cm, and 0.02 (±0.43) cm in RL, AP, and SI
directions, respectively. The PTV margin to compensate for lung cancer tumor variations uncertainties were 0.88, 0.98
and 2.68 cm in RL, AP and SI directions, which were maximal among all margin recipes.
Conclusions: 4DCT and CBCT imaging are appropriate to account for the tumor intra-fractional centroid, boundary
variations and inter-fractional set-up displacement. The PTV margin to compensate for lung cancer tumor variations
uncertainties can be obtained. Our results show that a conventional 1.0 cm margin in the SI plane dose not suffice to
compensate the geometrical variety of the tumor located in lower lobe and adhered to chest wall and diaphragm.
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Background
Lung cancer is one of the leading causes of death in can-
cer patients in China. According to the literature, 3-year
local control rate of the lung cancer is only 66% in con-
ventional conformal radiotherapy [1]. The stereotactic
body radiation therapy (SBRT) is a new technology which
can effectively improve the treatment effect of lung can-
cer. A meta-analysis of 34 lung cancer SBRT studies
including 2578 patients reported that 3-year local control
rate for tumors measuring greater than 3 cm was 87% [2].
SBRT delivers high dose in fewer fractions (3–10 frac-
tions) than conventional radiotherapy which may increase
toxicity in adjacent organs at risk (OAR). It is therefore
critical to minimize the irradiated volume of healthy tissue
when delivering the prescribed dose to tumor in SBRT.
However, a variety of geometrical uncertainty such as
respiratory motion [3, 4], baseline variation [5–8] and set-
up error [9], limit the precision of radiation therapy (RT)
for lung cancer. According to ICRU report 62#, internal
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margin (IM) and set-up margin (SM) should be included
in the PTV to compensate geometrical uncertainties in-
cluding tumor centroid movement [10], tumor boundary
[11, 12] and set-up displacement, especially in SBRT.
However, the tumor boundary displacement merely dis-
cussed about margin calculation previously. It would be
assessed in present study.
As a standard modality to compensate tumor motion,
four-dimensional CT (4DCT) has been generally applied
to the calculation of the extent margin of tumor motion
[13], and is also incorporated into treatment planning.
When only areas with tumor appearance are included in
the target volume definition, there is a significant reduc-
tion of the mean volume by the use of 4DCT [14]. Gener-
ally, the need of contour gross tumor volume (GTV) in
up to ten phases of respiration is a time-consuming pro-
cedure for the routine clinical use of 4DCT scans. To re-
duce the workload of multiple contour delineations in
4DCT, maximum intensity projection (MIP) and averaged
intensity (AI) of 4DCT image are reconstructed in order
to be used in the treatment planning, MIP provide a 3D
CT scan whose vowels’ values are the greatest vowels’ in-
tensity values throughout the 4D CT dataset. AI provides
a 3D CT scan whose vowels’ values are the arithmetic
mean of the 4D CT scans [15]. However, the tumor con-
toured with the MIP or AI series cannot totally represent
the true tumor size, location and shape, especially adhered
to chest wall or diaphragm [15]. To correctly assess the
tumor motion and tumor shape, ten phase of the 4DCT
were contoured in our study.
Tumor localization is also a significant issue in NSCLC
SBRT, the major focus has been the development of
image-guidance system. Several image guidance tech-
niques such as electronic portal imaging device (EPID)
[16] and CBCT [17], have been adapted to narrow the set-
up margin. Among them, three-dimensional (3D) match-
ing, coupled with CBCT provides results that have greater
accuracy than two-dimensional matching, coupled with
EPID [18]. Generally, with the repeating CBCT imaging,
intra-fractional and inter-fractional set-up displacement
can be assessed for the lung cancer patients’ set-up dis-
placement using KV X-ray,such as fluoroscopy, CBCT and
four dimensional CBCT (4D-CBCT) [19–21]. CBCT im-
aging is sufficient to account for the inter-fractional tumor
variation and setup variation based on the bone structure,
which was adopted in our study. Furthermore, size, pa-
tients characteristics are also significant factors to influent
patients’ set-up margin [22], but these factors are negli-
gible in the set-up margin.
The present study would evaluate changes in tumor mo-
tion magnitude and set-up error by 4DCT at planning and
CBCT at treatment, and calculated the clinical target vol-
ume (CTV)-planning target volume (PTV) margins to
compensate for these changes, which may minimize the
risk of complications and tumor failures. The aim of the
present study is to decide whether conventional 1.0 cm
margin in the SI plane and 0.5 cm margin in the other
plane suffice to compensate the geometrical variety of the
tumor adhere to chest wall and diaphragm.
Methods
Patient and tumor characteristics
Between February 2013 and June 2015, 20 patients were
recruited to this study to assess PTV margin. Table 1
summarizes the patient and tumor’s general information
and detailed characteristics.
The studies were approved by the Institutional Commit-
tee for Clinical Research and the Local Ethics Committee
in The First Affiliated Hospital, Xi’an Jiaotong University
of medical college. Eligible patients were given written in-
formed consent.
4DCT simulation and image acquisition
During the CT simulation, all patients were immobilized
using thermoplastic mask in the supine position with
arms raised above the head. Then, each patient received
a helical treatment planning three-dimensional computed
tomography (TP-3DCT) and an additional 4DCT simula-
tion under free breathing condition on a 16-slice CT scan-
ner (Big bore, Philips Medical Systems, Cleveland, OH).
For TP-3DCT, each scan’s rotation time took about 1 s
to acquire image dates. The other parameters were as
follows: pitch 0.85, 120KV and 400mAs. During 4DCT
scanning, the respiratory signal was acquired by a pres-
sure sensor (“pneumonia bellows”). The pressure in the
bellows decreases as the patient inhales, with the
Table 1 Patients and tumor generally characteristics of 20















Chest wall adherent 15
Diaphragm adherent 5
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opposite happening as the patient exhales. Then, the
pressure change was measured by a remote pressure
sensor which provided a direct-current voltage to an
analog-to-digital converter. 4DCT images were recon-
structed and then sorted into 10 respiratory phases,
with 0% representing end-inhalation and 50% repre-
senting end-exhalation. Prospectively phase-binned
image sets was been used to extract displacement
binned 4DCT. Both the TP-3DCT and 4DCT images
were reconstructed with a thickness of 3 mm and then
transferred to a Pinnacle V. 9.0y treatment planning
system (Philips Medical Systems, Fitchburg, USA).
Manual contouring and treatment planning
For target volume definition, the 4DCT phases display
the extreme of tumor positions for each spatial direction.
After the matching of CT-cubes between 4DCT phases
and 3DCT phase in the Philips treatment planning sys-
tem, GTV contours were manually delineated on the 10
phases of the 4DCT scan using the lung window setting
by the same physician to make the inter-observer lowest
as soon as possible (L = −600Hu, W = 1600Hu [20]), and
CTV4D was defined as GTV4D plus an isotropic margin
of 0.6 cm for adenoid carcinoma and the one of 0.8 cm
for squamous carcinoma. The combined volume of each
CTVs in 10 phases was defined as internal CTV4D
(ITV). The modification to form the PTV4D was per-
formed by adding an isotropic margin of 3 mm to ITV
to account for set-up inaccuracies in all direction (Fig. 1).
The PTV4D contours on 4DCT phases were projected to
the contour named PTV on the TP-3DCT.
For treatment planning, every patient received an indi-
vidual treatment plan and the plan calculation were per-
formed on 3DCT, 10 patients were treated with the
IMRT technology, and the others with conformal arc
technology. All patients were prescribed total doses of
48Gy in 4 fractions [16, 23, 24] with the 95% isodose
covering the PTV.
Tumor boundary change definition
Figure 2 shows tumor boundary change definition. Ten
beams with gantry angle 0° and 90° were used and
conformed to GTV of each phase with centroid of corre-
sponding GTV for each patient. The values of jaw location
in the RL, and SI directions with beam of angle 0° were col-
lected. Then the same values with beam of angle 90° were
also collected. The variation of these values represent the
boundary displacement in the RL, AP and SI direction.
CBCT simulation and image acquisition
The on-board imager integrated in a Synergy medical lin-
ear accelerator (Elekta, Stockholm, Sweden) was adopted
to acquire CBCT images. Before acquiring the image data,
each patient was immobilized in the same position as that
used in 4DCT scan. A 120 kV x-ray tube voltage and
400mAs current were used for generating middle-
resolution images. The scan angle was from −178° to 178°.
All CBCT images were reconstructed with a thickness of
3 mm. After each patient were initial positioned, a CBCT
was acquired and registered to the planning TP-3DCT
based on the location of vertebral bodies (bony land-
marks) (Fig. 3). The target position error was corrected by
shifting the treatment couch. If the position error was
≤2 mm in all three direction, the patient was treated with-
out shifting couch; else couch was shifted and a second
CBCT was acquired to measure the residual error until a
residual error was ≤2 mm [19]. At the end of treatment, a
CBCT scan was finally performed to assess the intra-
fractional set-up displacement.
Respiration motion analysis
Centroid position and boundary of the respective CTV4D
were calculated and compared. The centroid shift of re-
spective CTV4D was represented as tumor position vari-
ation, and the tumor boundary change of respective
CTV4D was represented as tumor shape variation during
respiration. The 3D spatial motion vector of the indi-
vidually CTV4D centroid and boundary variation were
evaluated according to the recipe as follows [25]
V ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
RL2 þ AP2 þ SI2
p
:
Fig. 1 Phase 0% of four-dimensional computed tomography (4DCT) image for an protocol NSCLC patient. (a) transverse (b) sagittal (c) coronal;
Gross tumor volume (GTV) of phase 0% in Red; Clinical target volume (CTV) of phase 0% in Green; Internal clinical target volume (ITV) in blue;
Planning target volume (PTV) in Yellow
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Margin calculation
Existing literature has proposed approaches to calculate
the PTV margin based on systematic and random uncer-
tainties (see Table 2) [8, 26–28], which were applied for
the PTV margin calculation in our study. Among these
approaches, the recipes approached by Stroom and van
Herk are widely adopted in current clinical treatment. In
all recipes, ∑ represents the standard deviation (SD) of
systematic errors and σ is the root-mean square of ran-
dom errors. In this study, the systematic errors include
the standard deviat55ion (SD) of the centroid movement
denoted as ∑centroid, the tumor boundary changes denoted
as ∑boundary and set-up displacement denoted as ∑setup of
each patient. As each patient had one 4DCT scan, the ran-
dom errors of the centroid and boundary changes were
zero, and the total random errors equal to set-up random
errors. As a result, the total SD of systematic errors ∑total











, σtotal = σsetup.
Data analysis
SPSS 19.0 was used for statistical analysis. Differences
were considered significant for P <0.05. For test of cor-
relation, it is Person’s rank test which was used.
Results
Tumor centroid and boundary changes
Figures 4 and 5 show the tumor boundary and cen-
troid changes for 20 patients. A positive value in the
right-left (RL), anterior-posterior (AP), and superior-
inferior (SI) directions represents a shift in the right,
anterior, and inferior directions, respectively. We did
not find any statistically significant correlation be-
tween tumor centroid displacement or boundary
changes and patients’ age. The mean 3D centroid
change value was 1.55 ± 0.46 cm, with a maximum at
2.33 cm. Tumor centroid had a greater mean changes
in SI direction than in other direction (SI vs RL: t =
0.587,P < 0.05; SI vs AP: t = 0.547, P < 0.05). The mean
3D boundary change value was 0.70 ± 0.33 cm, with a
Fig. 2 Phase 0% of four-dimensional computed tomography (4DCT) image for an protocol NSCLC patient. (a) coronal (b) sagittal; Gross tumor
volume (GTV) of phase 0 % (GTV0%) in Red; Gross target volume (GTV) of phase 50 % (GTV50%) in Green
Fig. 3 Precorrection cone-beam CT (CBCT) image for an protocol NSCLC patient in the thermoplastic mask. TP-3DCT GTV in Yellow; Precorrection
GTV in Red
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maximum at 1.40 cm. Tumor boundary motion had a
greater mean displacement in AP direction than in
other directions, but it is not statistically significant,
which is similar to the one observed by Gauthier
et al. [12]. In all direction, the average boundary
changes directions were toward to the centroid
changes directions, which means the tumor shrank as
expected.
Tumor set-up errors
Figure 6 shows tumor set-up errors in RL, AP, and
SI directions for 80 pre-correction CBCT fractions.
A positive value in the right-left (RL), anterior-
posterior (AP), and superior-inferior (SI) directions
represents a shift in the right, anterior, and inferior
directions, respectively. The maximum set-up error
were as large as 0.66 cm in RL direction, 0.54 cm in
AP direction, and 1.16 cm in SI direction. The aver-
age setup errors are 0.13 ± 3.15 cm,0.37 ± 2.76 cm
and 0.20 ± 5.73 cm in RL, AP and SI directions, re-
spectively. From the distribution, we could calculated
the probability of having set-up errors lager than
5 mm (which is the margin used for set-up margin)
and found it to be 15.0% in RL, 6.3% in AP, and
38.8% in SI directions, respectively. The mean set-up
errors had a greater value in SI direction than in
other directions. (SI vs AP: r = −0.609, p <0.05; SI vs
RL: r = −0.480, p > 0.05).
PTV margin
Table 3 shows the SDs of systematic (∑) and random (σ)
errors. One patient had one 4DCT scan at tumor CT
simulation, and therefore the random errors were zero for
tumor centroid and boundary displacement. Based on the
SDs of set-up systematic and random errors in previous
table, the pre-correction set-up margin was calculated and
showed in Table 4. Among all recipes, the maximum were
0.67, 0.69 and 1.21 cm in RL, AP and SI directions, which
were calculated with the recipe by van Herk et al. To com-
pensate all geometrical uncertain motioned above, the
total margin were calculated and showed in Table 4.
Among all recipes, the maximum were 0.88, 0.98 and
2.68 cm in RL, AP and SI directions, which were also
calculated with the recipe by van Herk et al.
Discussion
It is reported [29] that the tumor movement in lung is not
related to patient height, weight, cancer stage and lung
function, and therefore these issues were not included in
this study. We evaluated changes in tumor motion magni-
tude and set-up error by 4DCT scan at planning and
CBCT scan at treatment and calculated the margins to
compensate for these changes [16, 17]. To our knowledge,
this is the first study to report the evaluation of tumor
centroid, boundary changes and set-up displacement,
which are account into the margins calculation.
We admit that at the time we performed this study,
we did not perform Post-correction and post-treatment
CBCT to verify that set-up displacement and tumor
locatioin had not changed. However, [30, 31] existing lit-
eratures have shown that post-correction margins based
on bony structure are negligible to account into PTV
margin, which are less than 2 mm in three directions
[24]. Other literature has shown that inter-fractional
tumor position and breathing motion based on bony
Fig. 4 Boundary errors in RL,AP,and SI directions and 3D vector for
20 patients
Table 2 Summary of various published recommendations for
margins around target volumes (CTV)
Author Region Recipe
Stroom et al.(1999a) [26] PTV 2∑ + 0.7σ
Van Herk et al.(2000) [27] PTV 2.5∑ + 0.7σ





Snoke JJ (2007) PTV 2.5∑ + β(σ2 + σP2)1/2 − βσP
Symbols: ∑, standard deviation of systematic uncertainties; σ, standard
deviation of statistical (random) uncertainties. σP =0.64, β =0.84.
Fig. 5 Centroid position errors in RL,AP,and SI directions and 3D
vector for 20 patients
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structure during treatment are stable. Therefore, the
post-treatment margins are also negligible to account
into PTV margin. In addition, we did perform post-
correction and post-treatment CBCT on other patients
and found that the tumor with post-correction and post-
treatment displacement changed is negligible, and there-
fore the data have not yet been published.
The variation in the centroid changes between ITV
based from 4DCT and CTV based from 3DCT was
not significant [32]. Therefore, the intra-fractional
tumor motion on 4DCT different phase can represent
the one on the TP-3DCT. Intra-fractional tumor mo-
tion in present study was divided into tumor centroid
and boundary displacement under free-breathing con-
ditions. Centroid and boundary variation were col-
lected starting from 0% phase to ending at a phase of
maximum variation, which was 50% phase mostly. So
the variation of centroid and boundary were collected
starting from inferior direction to ending at superior
direction. In my study, A positive value in superior-
inferior (SI) directions represents a shift in the infer-
ior directions. So the values for centroid an boundary
in the graphs are negative values. Mori, S et al. [33]
quantified the magnitude of intra-fraction lung tumor
motion under free-breathing conditions using 4DCT
and reported the mean (±standard deviation) tumor
centroid motion were 0.19 (±0.16), 0.40 (±0.23), and
1.03 (±0.71)mm in the RL, AP, and SI directions re-
spectively, which was similar with the present study
result. Only the motion in SI direction was less than
present study. We presume that only a few lung tu-
mors were located in the lower lobe on previous
study, resulting in their small centroid changes in SI
direction.
Tumor boundary motion, which was merely dis-
cussed on previous PTV margin study, were quanti-
fied in present study and found that the maximum
were 0.57, 0.99, and 0.97 cm in RL, AP and SI direc-
tion respectively. We could calculated the probability
of having boundary motion lager than 5 mm and
found it to be 10.0% in RL, 40.0% in AP, and 7.5% in
SI directions, respectively. We presume that the
tumor located in lower lobe patients was adhered to
the diaphragm, resulting in their significant boundary
changes. We believe that the boundary changes in
intra-fractional variation is significant, especially in
SBRT treatment.
Set-up error in the present study was defined as the
shift from TP-3DCT to CBCT. This error includes the
inter-fractional set-up error based on bony structure.
The standard deviation of set-up systematic errors (∑)
are 0.24, 0.26 and 0.43 cm in RL, AP and SI directions.
The result was similar with the one observed by Worm,
E.S. et al., which was 0.23, 0.16 and 0.45 cm [31]. The
standard deviation of set-up random errors (∑) are 0.10,
0.08 and 0.20 cm in RL, AP and SI directions. The result
was also similar with the one observed by Li, W ea al,
which was 0.12, 0.13 and 0.17 cm with Performance Sta-
tus 0 patients stratified by Eastern Cooperative Oncology
Group performance [24]. The average setup errors are
0.13 ± 3.15 cm,0.37 ± 2.76 cm and 0.20 ± 5.73 cm in RL,
AP and SI directions, respectively. And the maximum
set-up margin in the present study was 0.67, 0.69 and
1.21 cm in RL, AP and SI directions calculated with van
Herk recipe. These result was similar with the study by
Wang L et al. [23], which assessed set-up margin using
three-dimensional CBCT and report it to be 0.9–1.0 cm
range. However, the study by Ueda Y et al. [16] assessed
set-up margin by shift from MTP-4DCT at planning to
MTP-cine at the treatment and reported it to be
0.52 cm in SI direction in 98% session’s calculated
Fig. 6 Set-up errors in in RL, AP, and SI directions and 3D vector for 80 fractions. Data were derived based on bony landmark alignments
Table 3 The Standard deviation of systematic (∑) and random
(σ) errors
∑ σ
RL AP SI RL AP SI
Centroid point 0.14 0.18 0.55
Boundary 0.19 0.21 0.17
Set-up 0.24 0.26 0.43 0.10 0.08 0.20
Symbols: ∑, standard deviation of systematic uncertainties; σ, standard
deviation of statistical (random) uncertainties
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Stroom recipe (Table 2). The margin in study above is
less than that in present study. We presume that their
set-up, which used Body Fix double-vacuum system, re-
sulted in their smaller set-up error.
The PTV margin also depends on the patient position-
ing techniques. Corradetti MN et al. [34] Stated that mar-
gins were 0.49 cm, 0.85 cm and 0.77 cm in RL, AP, and SI
direction calculated by the van Herk recipe, respectively,
which is smaller than the present result. We presume that
their set-up, which used the full-body vacuum cushion
system, resulted in their smaller inter-fractional error.
Many other studies on SBRT have adopted 5 mm as the
PTV margin using various advanced immobilized devices,
such as Microtron, BodyFix. These devices can obviously
reduce the PTV margin in the SBRT treatment for
NSCLC. However, these advanced devices cause more
time in the patients’ set-up procedure and bring more var-
iations in the time spent on the treatment couch [17].
A total PTV margin combining tumor centroid, bound-
ary changes and set-up displacement were 0.88, 0.98 and
2.68 cm in RL, AP and SI directions, respectively, which
were maximum among all margin recipes. According to
the comments of Table 5, the statistical assumption with
van Herk’s recipe is minimum absorbed dose to CTV is
95% for 90% of patients. It’s requirement about minimum
absorbed dose is high in realistic treatment plans, so the
bigger margin size are needed to meet the requirement.
This appoint is proved in my study, which shows that
among all recipes, the maximum margin were calculated
with the recipe by van Herk et al. And the requirement of
Parker’s recipe about minimum absorbed dose is the same
as one of van Herk’s, but the probability lever is not speci-
fied. And the results in my study shows that the margin
calculated with Parker’s recipe is less than one with van
Herk’s recipe.
Many studies stated that PTV margin was 0.5 cm in the
axial plane and 1.0 cm in the cranial-caudal plane in all di-
rections in the study on SBRT for NSCLC [20, 35–37].
The results were less than the one observed in SI direction
of the present study. In conclusion, a 0.5 cm margin in the
axial plane suffices to compensate the geometrical variety;
nevertheless, a 1.0 cm margin in the SI plane is dose not
compensated the geometrical variety in the present study,
which the tumor located in lower lobe is adhered to chest
wall and diaphragm.
Conclusions
4DCT imaging is appropriate to account for the intra-
fractional tumor centroid position, and boundary varia-
tions, and CBCT imaging is appropriate to account for
the inter-fractional tumor set-up variation. We observed
that the large tumor geometrical motion in lung tumor
located in lower lobe and adhered to chest wall and dia-
phragm on SBRT for NSCLC and PTV margin could be
as large as 0.88, 0.98 and 2.68 cm in RL, AP and SI di-
rections, respectively. However, a conventional 1.0 cm
margin in the SI plane dose not suffice to compensate
the geometrical variety of the tumor adhere to chest wall
and diaphragm.
Table 4 CTV margin changes of NSCLC patients
Author Recipe Margin through set-up errors Margin through all variation
ML AP SI ML AP SI
Stroom et al.
(1999a) [26]
2∑ + 0.7σ 0.55 0.57 0.99 0.72 0.79 2.18
van Herk et al.
(2000) [27]







0.50 0.52 0.90 0.66 0.75 2.06
Snoke JJ
(2007)
2.5∑ + β(σ2 + σP
2)1/2 − βσP 0.60 0.64 1.09 0.82 0.93 2.57
Table 5 Summary of various published recommendations for margins around target volumes
Author Recipe Comments
Stroom et al. (1999a) [26] 2∑ + 0.7σ 95% absorbed dose to on average 99% of CTV tested in realistic plans.
Van Herk et al. (2000) [27] 2.5∑ + 0.7σ Minimum absorbed dose to CTV is 95% for 90% of patients. Analytical solution for perfect
conformation.





95% minimum absorbed dose and 100% absorbed dose for 95% of volume. Probability levels not
specified.
Snoke JJ (2007) 2.5∑ + β(σ2 + σP2)1/2
− βσP
Minimum 95% of the prescribed dose for 90% of patients
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